15.19
Takeda Pharmaceutical Co Adr stock is traded at $15.19, with a volume of 4.31M.
It is up +1.40% in the last 24 hours and up +2.36% over the past month.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
See More
Previous Close:
$14.98
Open:
$15.28
24h Volume:
4.31M
Relative Volume:
2.51
Market Cap:
$47.98B
Revenue:
$30.25B
Net Income/Loss:
$1.37B
P/E Ratio:
35.68
EPS:
0.4257
Net Cash Flow:
$5.08B
1W Performance:
+0.33%
1M Performance:
+2.36%
6M Performance:
+6.67%
1Y Performance:
+12.27%
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Compare TAK with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
TAK
Takeda Pharmaceutical Co Adr
|
15.19 | 47.98B | 30.25B | 1.37B | 5.08B | 0.4257 |
![]()
ZTS
Zoetis Inc
|
159.61 | 71.47B | 9.26B | 2.49B | 2.30B | 5.47 |
![]()
HLN
Haleon Plc Adr
|
10.45 | 47.20B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
14.85 | 17.02B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
307.36 | 13.80B | 2.76B | 1.11B | 898.10M | 22.77 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Mar-16-23 | Upgrade | BofA Securities | Neutral → Buy |
Jul-19-22 | Upgrade | Cowen | Market Perform → Outperform |
Oct-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Apr-19-21 | Downgrade | JP Morgan | Overweight → Neutral |
Nov-01-19 | Initiated | Cowen | Market Perform |
Aug-15-19 | Downgrade | Daiwa Securities | Outperform → Neutral |
View All
Takeda Pharmaceutical Co Adr Stock (TAK) Latest News
Asian ADRs Take A Hit As S&P Asia 50 Dips - Finimize
Asian Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading - TradingView
UK's Health Agency Endorses Pfizer's Blood Cancer Combo Therapy As First For Untreated Hodgkin Lymphoma Patients - Benzinga
TAK vs. DSNKY: Which Stock Should Value Investors Buy Now? - Yahoo Finance
PD Stock on the Rise: A Promising Investment - The InvestChronicle
TAK or DSNKY: Which Is the Better Value Stock Right Now? - Yahoo Finance
Vital Energy Inc (VTLE) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
China Liberal Education Holdings Ltd: A Comprehensive Look at the Stock’s Ups and Downs - The InvestChronicle
Takeda Pharmaceutical Stock (NYSE: TAK): Strategic Focus on Oncology and Growth Opportunities - Value the Markets
Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds - Seeking Alpha
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Charles Schwab Trying To Close In On Key Technical Measure - Inkl
Takeda Pharmaceutical Co ADR (TAK) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
Takeda Pharmaceutical ADR Trying To Close In On Key Technical Measure - Investor's Business Daily
XFOR: Receives €28.5 Upfront for Licensing Agreement with Norgine… - MSN
TAK vs. DSNKY: Which Stock Is the Better Value Option? - Nasdaq
Ex-Intern Becomes Billionaire in Australia Pharmacy Merger - MSN
Vyvanse Leaks: Beyond The Headlines - Truth or Fiction
IgA nephropathy Clinical Trials and Pipeline 2025: EMA, PDMA, - openPR
IgA nephropathy Clinical Trials and Pipeline Assessment: EMA, - openPR
Procter & Gamble Co (PG) expanding its growth trajectory ahead - SETE News
Prepare Yourself for Liftoff: AMKOR Technology Inc (AMKR) - SETE News
Takeda Pharmaceutical Co ADR [TAK] President, Plasma-Derived Ther makes an insider purchase of 19,073 shares worth 0.28 million. – Knox Daily - Knox Daily
Advanced Drainage Systems Inc [WMS] Records 50-Day SMA of $122.78 - Knox Daily
GFL Shares Experience Surge in Value - Knox Daily
UBS Group AG [UBS] Shares Rise 2.39 % on Thursday - Knox Daily
Takeda Pharmaceutical Co ADR (TAK)’s stock price range in the last year - US Post News
Inmode Ltd (INMD) Stock Price and Analyst Predictions - The News Heater
Recent Insider Activity Could Benefit Wabash National Corp (WNC) - Knox Daily
Analyzing Takeda Pharmaceutical Co ADR (TAK) After Recent Trading Activity - Knox Daily
Takeda signals 2025 growth with raised guidance, JPY 100B buyback, and new leadership transition - MSN
Ascentage Has First U.S. Biotech IPO of 2025, Raising $126M to Bring Its Cancer Meds to the World - Dealbreaker
Keros Therapeutics seals $200M deal with Takeda - Investing.com
Japan’s Takeda launches innovation centre in Bengaluru; to hire 750 in 2025 - Deccan Herald
Weekly Upgrades and Downgrades - InvestorPlace
Takeda Pharmaceutical Co Adr Stock (TAK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):